Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
15.32
-0.20 (-1.29%)
At close: Sep 2, 2025, 4:00 PM
15.40
+0.08 (0.52%)
After-hours: Sep 2, 2025, 7:17 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Arcutis Biotherapeutics stock have a consensus rating of "Strong Buy" and an average price target of $19, which forecasts a 24.02% increase in the stock price over the next year. The lowest target is $15 and the highest is $22.
Price Target: $19 (+24.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | +43.60% | Aug 7, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $18 | Hold | Initiates | $18 | +17.49% | Jul 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +30.55% | May 23, 2025 |
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +30.55% | Apr 9, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 3, 2025 |
Financial Forecast
Revenue This Year
338.95M
from 196.54M
Increased by 72.46%
Revenue Next Year
447.40M
from 338.95M
Increased by 32.00%
EPS This Year
-0.47
from -1.16
EPS Next Year
0.13
from -0.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 364.4M | 491.8M | |||
| Avg | 339.0M | 447.4M | |||
| Low | 316.7M | 410.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 85.4% | 45.1% | |||
| Avg | 72.5% | 32.0% | |||
| Low | 61.1% | 21.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.37 | 0.42 | |||
| Avg | -0.47 | 0.13 | |||
| Low | -0.51 | -0.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.